Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Liminal BioSciences Inc. LMNL

Liminal BioSciences is a biopharmaceutical company focused on the discovery and development of novel, small molecule drug candidates for the treatment of patients suffering from fibrotic or inflammatory diseases that have a high unmet medical need. Liminal BioSciences operates on an integrated basis from our talent hubs in Laval, Quebec, Canada, and Cambridge, UK. Our common shares are listed for trading on the Nasdaq Global Market.


NDAQ:LMNL - Post by User

Comment by GunnerGon Jul 13, 2021 1:46pm
28 Views
Post# 33536468

RE:Drop since FDA approval actually 50%

RE:Drop since FDA approval actually 50%When trading resumed after hours, it started at $7.03  and fallen to a low of $3.52.

50% drop since FDA announcement.  Doesn't seem logical with a drug approval and a PRV.

I assume that selling the drug line and 30% of the PRV for $5M is being considered a dumb move.  Also, sold plasma collection facilities for $17M.  There is nothing left except the cash which LMNL will blow through in a year easy.

LOL  Sold 30% of PRV (thats a $30M value) for $5M only two weeks before approval. Through in Ryplazim for nothing (LMNL's only revenue).

<< Previous
Bullboard Posts
Next >>